Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adial Pharmaceuticals

0.3229
-0.0122-3.64%
Volume:2.03M
Turnover:634.20K
Market Cap:5.09M
PE:-0.21
High:0.3290
Open:0.3090
Low:0.3000
Close:0.3351
Loading ...

Adial Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
15 May

Adial Pharmaceuticals Receives Milestone Payment From Adovate Following Initiation of Phase 1 Study

THOMSON REUTERS
·
13 May

Adial Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
10 May

BRIEF-Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA

Reuters
·
08 May

Adial Pharmaceuticals Inc - FDA Meeting Scheduled for July 25, 2025

THOMSON REUTERS
·
08 May

Adial Pharmaceuticals Granted End of Phase 2 Meeting From the U.S. Food and Drug Administration

THOMSON REUTERS
·
08 May

Press Release: Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Dow Jones
·
02 May

Adial Pharmaceuticals Expands Intellectual Property Portfolio With New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

THOMSON REUTERS
·
01 May

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

GlobeNewswire
·
01 May

EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders

Benzinga
·
01 May

Adial Pharmaceuticals Appoints Tony Goodman as COO

TIPRANKS
·
22 Mar

Adial Pharmaceuticals FY 2024 GAAP EPS $(2.72) Beats $(2.97) Estimate

Benzinga
·
04 Mar

Adial Pharmaceuticals expects cash to fund operations into 2H of 2025

TIPRANKS
·
04 Mar

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

GlobeNewswire
·
04 Mar

BUZZ-Adial Pharma jumps on regulatory pathway for alcohol-use disorder drug

Reuters
·
25 Feb

Adial Pharmaceuticals Advances AD04 with FDA Approval

TIPRANKS
·
25 Feb

BRIEF-Adial Pharma Receives Positive Response From FDA Meeting Regarding Vitro Bridging Strategy For AD04

Reuters
·
25 Feb

Adial says FDA feedback confirms proposed strategy to AD04 Phase 3 formulation

TIPRANKS
·
25 Feb

Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed in Vitro Bridging Strategy for Ad04

THOMSON REUTERS
·
25 Feb

Adial Pharmaceuticals- Moves Forward With Manufacturing Clinical Supplies for Phase 3 Program in 2025

THOMSON REUTERS
·
25 Feb